论文部分内容阅读
目的：研究GST－π基因表达与卵巢癌的分化程度、临床分期、化疗效果的关系，探讨其临床意义。方法：免疫组织化学ABC法。结果：有化疗史专GST－π染色阳性的百分率为80．0％，无化疗史者为54．2％（P＜0．05）。表达阳性的33例中，近期化疗有效率为27．3％，表达明性16例中，近期化疗有效率为56．3％（P＜0．05）。随着分化程度的降低，阳性和强阳性反应频率增高。晚期肿瘤（Ⅲ、Ⅳ+复发）表达阳性和强阳性的比例明显增加。结论：GST－π的过度表达与卵巢癌的分化程度、临床分期、乃至常用抗癌药物的耐药有关，可能是一种预后不良的肿瘤标志物。
Objective: To study the relationship between the expression of GST-π gene and the differentiation, clinical stage and chemotherapeutic effect of ovarian cancer and to explore the clinical significance. Methods: Immunohistochemical ABC method. Results: The positive rate of GST-π staining in the history of chemotherapy was 80.0%, while the rate of non-chemotherapy history was 54.2% (P <0.05). Among the 33 positive cases, the effective rate of chemotherapy was 27.3% in the recent period, and the effective rate of chemotherapy in the 16 cases with immediate expression was 56.3% (P <0.05). With the degree of differentiation decreased, positive and strong positive reaction frequency increased. The ratio of positive and strong positive expression of advanced tumors (Ⅲ, Ⅳ + recurrence) was significantly increased. Conclusion: The overexpression of GST-π is related to the degree of differentiation, clinical stage and even the resistance of commonly used anticancer drugs, which may be a tumor marker with poor prognosis.